Title:
CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2018/028647
Kind Code:
A1
Abstract:
Provided are single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) comprising one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
Inventors:
FAN XIAOHU (CA)
ZHUANG QIUCHUAN (CN)
WANG PINGYAN (CN)
WANG LIN (CN)
YANG LEI (CN)
HAO JIAYING (CN)
ZHAO DAN (CN)
HE XIAN (CN)
ZHUANG QIUCHUAN (CN)
WANG PINGYAN (CN)
WANG LIN (CN)
YANG LEI (CN)
HAO JIAYING (CN)
ZHAO DAN (CN)
HE XIAN (CN)
Application Number:
PCT/CN2017/096938
Publication Date:
February 15, 2018
Filing Date:
August 10, 2017
Export Citation:
Assignee:
LEGEND BIOTECH USA INC (US)
NANJING LEGEND BIOTECH CO LTD (CN)
LEGEND BIOTECH IRELAND LTD (IE)
NANJING LEGEND BIOTECH CO LTD (CN)
LEGEND BIOTECH IRELAND LTD (IE)
International Classes:
C07K19/00; A61K39/395; A61P35/00; A61P35/02; C12N5/10
Domestic Patent References:
| WO2016014789A2 | 2016-01-28 | |||
| WO2016094304A2 | 2016-06-16 | |||
| WO2015120187A1 | 2015-08-13 |
Foreign References:
| CN105384825A | 2016-03-09 | |||
| CN104379179A | 2015-02-25 | |||
| CN104583230A | 2015-04-29 | |||
| EP3029067A1 | 2016-06-08 | |||
| CN105658671A | 2016-06-08 |
Other References:
HOFFMANN, P. ET AL.: "Serial killing of tumor cells by cytotoxic T cells redirected with a CD 19-/ CD 3-bispecific single-chain antibody construct", INT. J. CANCER, 1 February 2005 (2005-02-01), XP002335808
HEGDE, M. ET AL.: "Tandem CAR T cells targeting HER2 and IL 13Ra2 mitigate tumor antigen escape", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 126, no. 8, 1 August 2016 (2016-08-01), pages 3036 - 3052, XP055462487
See also references of EP 3475307A4
HEGDE, M. ET AL.: "Tandem CAR T cells targeting HER2 and IL 13Ra2 mitigate tumor antigen escape", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 126, no. 8, 1 August 2016 (2016-08-01), pages 3036 - 3052, XP055462487
See also references of EP 3475307A4
Attorney, Agent or Firm:
CHENG & PENG INTELLECTUAL PROPERTY LAW OFFICE (CN)
Download PDF: